litlas
Log inCreate account

Elke Jäger

Active 1981–2025

79
Papers
18,586
Citations
72
h-index
76
i10-index

Citations

Citations per year for Elke Jäger1983: 2 citations1984: 1 citations1988: 1 citations1990: 5 citations1991: 1 citations1992: 1 citations1993: 1 citations1995: 1 citations1996: 10 citations1997: 28 citations1998: 53 citations1999: 72 citations2000: 118 citations2001: 132 citations2002: 176 citations2003: 141 citations2004: 162 citations2005: 129 citations2006: 122 citations2007: 102 citations2008: 116 citations2009: 103 citations2010: 131 citations2011: 120 citations2012: 103 citations2013: 94 citations2014: 124 citations2015: 81 citations2016: 120 citations2017: 115 citations2018: 119 citations2019: 426 citations2020: 493 citations2021: 615 citations2022: 527 citations2023: 390 citations2024: 574 citations2025: 248 citations2026: 5 citations1985–1987: no citations, so these years are not shown1989: no citations, so this year is not shown1994: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,730 citing papers, 24.4% of this breakdownChina: 735 citing papers, 10.4% of this breakdownGermany: 609 citing papers, 8.6% of this breakdownUnited Kingdom: 425 citing papers, 6% of this breakdownItaly: 366 citing papers, 5.2% of this breakdownJapan: 364 citing papers, 5.1% of this breakdownFrance: 248 citing papers, 3.5% of this breakdownNetherlands: 235 citing papers, 3.3% of this breakdownSwitzerland: 227 citing papers, 3.2% of this breakdownAustralia: 169 citing papers, 2.4% of this breakdownCanada: 167 citing papers, 2.4% of this breakdownBelgium: 150 citing papers, 2.1% of this breakdown
0%24.4%Other 23.4%

Institutions

Fields

  • Medicine55.6%
  • Immunology and Microbiology24.3%
  • Biochemistry, Genetics and Molecular Biology17.3%
  • Agricultural and Biological Sciences0.9%
  • Engineering0.4%
  • Materials Science0.3%
  • Other1.2%

Topics

  • Immunotherapy and Immune Responses9.9%
  • Gastric Cancer Management and Outcomes6.4%
  • Cancer Immunotherapy and Biomarkers5.5%
  • Immune Cell Function and Interaction4.6%
  • CAR-T cell therapy research4%
  • vaccines and immunoinformatics approaches3.5%
  • Other66.1%

Coauthors

All papers

Open in search
  1. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

    Authors: Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk, Thorsten Oliver Goetze, Johannes Meiler, Stefan Kasper, Hans‐Georg Kopp, Frank Mayer, Georg Martin Haag, Kim Barbara Luley, Udo Lindig, Wolff Schmiegel, Michael Pohl, Jan Stoehlmacher, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Wolfgang Fischbach, Rolf Mahlberg, Jörg Trojan, Michael Koenigsmann, Uwe M. Martens, Peter Thuss‐Patience, Matthias Egger, Andreas Block, Volker Heinemann, Gerald Illerhaus, Markus Moehler, Michael Schenk, Frank Kullmann, Dirk Behringer, Michael Heike, Daniel Pink, Christian Teschendorf, Carmen Löhr, Helga Bernhard, Gunter Schuch, Volker Rethwisch, Ludwig Fischer von Weikersthal, Jörg T. Hartmann, Michael Kneba, S Daum, Karsten Schulmann, J. Weniger, Sebastian Belle, Timo Gaiser, Fuat Oduncu, Martina Güntner, Wael Hozaeel, Alexander Reichart, Elke Jäger, Thomas Kraus, Stefan Mönig, Wolf O. Bechstein, Martin Schüler, Harald Schmalenberg, Ralf‐Dieter Hofheinz - The Lancet 2019 cited by 2,583

  2. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

    Authors: Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk, Hans‐Georg Kopp, Georg Martin Haag, Kim Barbara Luley, Johannes Meiler, Nils Homann, Sylvie Lorenzen, Harald Schmalenberg, Stephan Probst, Michael Koenigsmann, Matthias Egger, Nicole Prasnikar, Karel Caca, Jörg Trojan, Uwe M. Martens, Andreas Block, Wolfgang Fischbach, Rolf Mahlberg, Michael Clemens, Gerald Illerhaus, Katja Zirlik, Dirk Behringer, Wolff Schmiegel, Michael Pohl, Michael Heike, Ulrich Ronellenfitsch, Martin Schüler, Wolf O. Bechstein, Alfred Königsrainer, Timo Gaiser, Peter Schirmacher, Wael Hozaeel, Alexander Reichart, Thorsten Oliver Goetze, Mark Sievert, Elke Jäger, Stefan Mönig, Andrea Tannapfel - The Lancet Oncology 2016 cited by 739

  3. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors

    Authors: Nicolás Gonzalo Núñez, Fiamma Berner, Ekaterina Friebel, Susanne Unger, Nina Wyss, Julia M. Martínez Gómez, Mette-Triin Purde, Rebekka Niederer, Maximilian Porsch, Christa Lichtensteiger, Rafaela Kramer, Michael Erdmann, Christina Schmitt, Lucie Heinzerling, Marie-Therese Abdou, Julia Karbach, Dirk Schadendorf, Lisa Zimmer, Selma Ugurel, Niklas Klümper, Michael Hölzel, Laura Power, Stefanie Kreutmair, Mariaelena Capone, Gabriele Madonna, Lacin Cevhertas, Anja Heider, Teresa Amaral, Omar Hasan Ali, David Bomze, Florentia Dimitriou, Stefan Diem, Paolo A. Ascierto, Reinhard Dummer, Elke Jäger, Christoph Driessen, Mitchell P. Levesque, Willem van de Veen, Markus Joerger, Martin Früh, Burkhard Becher, Lukas Flatz - Med 2023 cited by 122

  4. Anti-CCR4 mAb selectively depletes effector-type FoxP3 + CD4 + regulatory T cells, evoking antitumor immune responses in humans

    Authors: Daisuke Sugiyama, Hiroyoshi Nishikawa, Yuka Maeda, Megumi Nishioka, Atsushi Tanemura, Ichiro Katayama, Sachiko Ezoe, Yuzuru Kanakura, Eiichi Sato, Yasuo Fukumori, Julia Karbach, Elke Jäger, Shimon Sakaguchi - National Academy of Sciences, Proceedings of the National Academy of Sciences 2013 cited by 620

  5. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

    Authors: Annika Nelde, Tatjana Bilich, Jonas S. Heitmann, Yacine Maringer, Helmut R. Salih, Malte Roerden, Maren Lübke, Jens Bauer, Jonas Rieth, Marcel Wacker, Andreas Peter, Sebastian Hörber, Bjoern Traenkle, Philipp D. Kaiser, Ulrich Rothbauer, Matthias Becker, Daniel Junker, Gérard Krause, Monika Strengert, Nicole Schneiderhan‐Marra, Markus F. Templin, Thomas Joos, Daniel J. Kowalewski, Vlatka Stos‐Zweifel, Michael Fehr, Armin Rabsteyn, Valbona Mirakaj, Julia Karbach, Elke Jäger, Michael D. Graf, Lena-Christin Gruber, David Rachfalski, Beate Preuß, Ilona Hagelstein, Melanie Märklin, Tamam Bakchoul, Cécile Gouttefangeas, Oliver Kohlbacher, Reinhild Klein, Stefan Stevanović, Hans-Georg Rammensee, Juliane S. Walz - Nature Immunology 2020 cited by 641

  6. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer

    Authors: Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk, Gerald Illerhaus, Uwe M. Martens, Jan Stoehlmacher, Harald Schmalenberg, Kim Barbara Luley, Nicole Prasnikar, Matthias Egger, Stephan Probst, Helmut Messmann, Markus Moehler, Wolfgang Fischbach, Jörg T. Hartmann, Frank Mayer, Heinz‐Gert Höffkes, Michael Koenigsmann, Dirk Arnold, Thomas Kraus, Kersten Grimm, Stefan Berkhoff, Stefan Post, Elke Jäger, Wolf O. Bechstein, Ulrich Ronellenfitsch, Stefan Mönig, Ralf‐Dieter Hofheinz - JAMA Oncology 2017 cited by 474

  7. A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

    Authors: Jonas S. Heitmann, Tatjana Bilich, Claudia Tandler, Annika Nelde, Yacine Maringer, Maddalena Marconato, Julia Reusch, Simon Jäger, Monika Denk, Marion Richter, Leonard Anton, Lisa M. Weber, Malte Roerden, Jens Bauer, Jonas Rieth, Marcel Wacker, Sebastian Hörber, Andreas Peter, Christoph Meisner, Imma Fischer, Markus Löffler, Julia Karbach, Elke Jäger, Reinhild Klein, Hans‐Georg Rammensee, Helmut R. Salih, Juliane S. Walz - Nature 2021 cited by 275

  8. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial

    Authors: Matthias Kloor, Miriam Reuschenbach, Claudia Pauligk, Julia Karbach, Mohammad‐Reza Rafiyan, Salah‐Eddin Al‐Batran, Mirjam Tariverdian, Elke Jäger, Magnus von Knebel Doeberitz - Clinical Cancer Research 2020 cited by 139

  9. Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers

    Authors: Tuuli Ranki, Sari Pesonen, Akseli Hemminki, Kaarina Partanen, Kalevi Kairemo, Tuomo Alanko, Johan Lundin, Nina Linder, Riku Turkki, Ari Ristimäki, Elke Jäger, Julia Karbach, Claudia Wahle, Matti Kankainen, Charlotta Backman, Mikael von Euler, Elina Haavisto, Tiina Hakonen, Raita Heiskanen, Magnus Jäderberg, Juuso Juhila, Petri Priha, Laura Suoranta, Lotta Vassilev, Antti Vuolanto, Timo Joensuu - Journal for ImmunoTherapy of Cancer 2016 cited by 202

  10. Validity of the Six-Minute Walk Test in Cancer Patients

    Authors: Katharina Schmidt, Lutz Vogt, Christian Thiel, Elke Jäger, Winfried Banzer - International Journal of Sports Medicine 2013 cited by 355

  11. Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

    Authors: Salah‐Eddin Al‐Batran, J. T. Hartmann, Stephan Probst, Harald Schmalenberg, Stephan Hollerbach, Ralf‐Dieter Hofheinz, Volker Rethwisch, G. Seipelt, Nils Homann, G. Wilhelm, Gunter Schuch, Jan Stoehlmacher, Hans Günter Derigs, Susanna Hegewisch‐Becker, Johannes Grossmann, Claudia Pauligk, Akin Atmaca, Carsten Bokemeyer, Alexander Knuth, Elke Jäger - Journal of Clinical Oncology 2008 cited by 784

  12. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform

    Authors: Erkko Ylösmäki, Leena Ylösmäki, Manlio Fusciello, Beatriz Martins, Petra Ahokas, Hanne Cojoc, Arttu Uoti, Sara Feola, Anna Kreutzman, Tuuli Ranki, Julia Karbach, Tapani Viitala, Petri Priha, Elke Jäger, Sari Pesonen, Vincenzo Cerullo - Molecular Therapy — Oncolytics 2021 cited by 52

  13. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis

    Authors: Yelena Y. Janjigian, Dominique Werner, Claudia Pauligk, K. Steinmetz, David P. Kelsen, Elke Jäger, H. Altmannsberger, E. Robinson, Laura J. Tafe, Laura H. Tang, Manish A. Shah, Salah‐Eddin Al‐Batran - Annals of Oncology 2012 cited by 367

  14. Phase I Clinical Trial of Mixed Bacterial Vaccine (Coley's Toxins) in Patients with NY-ESO-1 Expressing Cancers: Immunological Effects and Clinical Activity

    Authors: Julia Karbach, Antje Neumann, Kathrin Brand, Claudia Wahle, Ekkehard Siegel, Markus Maeurer, Erika Ritter, Takamasa Tsuji, Sacha Gnjatic, Lloyd J. Old, Gerd Ritter, Elke Jäger - Clinical Cancer Research 2012 cited by 99

  15. Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination

    Authors: Yacine Maringer, Annika Nelde, Sarah M. Schroeder, J. Schuhmacher, Sebastian Hörber, Andreas Peter, Julia Karbach, Elke Jäger, Juliane S. Walz - Science Immunology 2022 cited by 73

  16. Acetylation of Stat1 modulates NF-κB activity

    Authors: Oliver H. Krämer, Daniela Baus, Shirley K. Knauer, Stefan Stein, Elke Jäger, Roland H. Stauber, Manuel Grez, Edith Pfitzner, Thorsten Heinzel - Genes & Development 2006 cited by 214

  17. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells

    Authors: Atsushi Tanaka, Hiroyoshi Nishikawa, Shinsuke Noguchi, Daisuke Sugiyama, Hiromasa Morikawa, Yoshiko Takeuchi, Danbee Ha, Naoya Shigeta, Toshio Heike, Yuka Maeda, Takuro Saito, Yoshinori Shinohara, Yoshihiro Kameoka, Keiko Iwaisako, Fumihiko Monma, Kohshi Ohishi, Julia Karbach, Elke Jäger, Kenichi Sawada, Naoyuki Katayama, Naoto Takahashi, Shimon Sakaguchi - The Journal of Experimental Medicine 2019 cited by 93

  18. High-risk additional chromosomal abnormalities at low blast counts herald death by CML

    Authors: Rüdiger Hehlmann, Astghik Voskanyan, Michael Lauseker, Markus Pfirrmann, Lida Kalmanti, Sébastien Rinaldetti, Katharina Kohlbrenner, Claudia Haferlach, Brigitte Schlegelberger, Alice Fabarius, Wolfgang Seifarth, Birgit Spieß, Patrick Wuchter, Stefan W. Krause, Hans‐Jochem Kolb, Andreas Neubauer, Dieter K. Hossfeld, Christoph Nerl, Aloïs Gratwohl, Gabriela M. Baerlocher, Andreas Burchert, Tim H. Brümmendorf, Jörg Hasford, Andreas Hochhaus, Susanne Saußele, Michele Baccarani, for the SAKK and the German CML Study Group, Ludwig Fischer von Weikersthal, Markus Hahn, Günter Schlimok, Dietmar Reichert, Jan Janßen, Uwe M. Martens, Peter Majunke, Peter Reichert, Kai Neben, Stefan Korsten, Ch. Scholz, Bernd Oldenkott, Jörg Heßling, D. Kingreen, Christian Sperling, C. Schelenz, I. W. Blau, A. Urmersbach, W. D. Ludwig, Philipp le Coutre, R. Arnold, Maike de Wit, Antonio Pezzutto, E. Schäfer, Roland Schroers, A. Lochter, Dirk Behringer, Y. Ko, St. Weidenhöfer, Walter Verbeek, Peter Brossart, Guido Trenn, W Pommerien, J. Krauter, G. Döering, H. Munzinger, C. Diekmann, Bernd Hertenstein, Sebastian Stier, F. Möller-Faßbender, Mathias Hänel, T. Zöller, C. Lamberti, Babette Koch, A. Henzel, Siegfried Wagner, A. Schmalenbach, M. Hoffknecht, Gerhard Ehninger, Alexander Kiani, Thomas Illmer, Carlo Aul, Michael Flaßhove, F. Henneke, M. Simon, Lothar Müller, Heiko Becker, R. F. Janz, Michael J. Eckart, Roland J. Fuchs, Frank Schlegel, Mohammad Amen Wattad, R. Rudolph, Dietrich W. Beelen, A Lindemann, D. Linck, Wassman, Elke Jäger, Salah‐Eddin Al‐Batran, T Reiber, Cornelius F. Waller, Heinz‐Gert Hoeffkes, L.S. Schulz and 154 more - Leukemia 2020 cited by 92

  19. Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

    Authors: Elke Jäger, Yao-Tseng Chen, Jan W. Drijfhout, Julia Karbach, Mark Ringhoffer, Dirk Jäger, Michael Arand, Hisashi Wada, Yuji Noguchi, Elisabeth Stockert, Lloyd J. Old, Alexander Knuth - The Journal of Experimental Medicine 1998 cited by 725

  20. NY‐ESO‐1: Review of an Immunogenic Tumor Antigen

    Authors: Sacha Gnjatic, Hiroyoshi Nishikawa, Achim A. Jungbluth, Ali O. Güre, Gerd Ritter, Elke Jäger, Alexander Knuth, Yao‐Tseng Chen, Lloyd J. Old - Advances in cancer research 2006 cited by 455

  21. “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells

    Authors: Nicola Mitwasi, Anja Feldmann, Claudia Arndt, Stefanie Koristka, Nicole Berndt, Justyna Jureczek, Liliana R. Loureiro, Ralf Bergmann, Domokos Máthé, Nikolett Hegedűs, Tibor Kovács, Congcong Zhang, Pranav Oberoi, Elke Jäger, Barbara Seliger, Claudia Rössig, Achim Temme, Jiří Eitler, Torsten Tonn, Marc Schmitz, Jessica C. Hassel, Dirk Jäger, Winfried S. Wels, Michael Bachmann - Scientific Reports 2020 cited by 83

  22. Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

    Authors: Jonas S. Heitmann, Claudia Tandler, Maddalena Marconato, Annika Nelde, Timorshah Habibzada, Susanne M. Rittig, Christian M. Tegeler, Yacine Maringer, Simon U. Jaeger, Monika Denk, Marion Richter, Melek Tutku Oezbek, Karl‐Heinz Wiesmüller, Jens Bauer, Jonas Rieth, Marcel Wacker, Sarah M. Schroeder, Naomi Hoenisch Gravel, Jonas Scheid, Melanie Märklin, Annika Henrich, Boris Klimovich, Kim L. Clar, Martina S. Lutz, Samuel J. Holzmayer, Sebastian Hörber, Andreas Peter, Christoph Meisner, Imma Fischer, Markus Löffler, Caroline Anna Peuker, Stefan Habringer, Thorsten Oliver Goetze, Elke Jäger, Hans‐Georg Rammensee, Helmut R. Salih, Juliane S. Walz - Nature Communications 2023 cited by 35

  23. Expression of MAGE genes in primary and metastatic cutaneous melanoma

    Authors: Francis Brasseur, Donata Rimoldi, Danielle Líénard, Bernard Lethé, S Carrel, Flavio Arienti, Ludwig Suter, R Vanwijck, André Bourlond, Yves Humblet, Angelo Vacca, Marina Conese, Thierry Lahaye, Gérard Degiovanni, Rika Deraemaecker, M. Beauduin, Xavier Sastre, E. Salamon, Brigitte Dréno, Elke Jäger, A. Knuth, Christine Chevreau, Stefan Suciu, Jean‐Marie Lachapelle, P Pouillart, Giorgio Parmiani, Ferdy J. Lejeune, Jean‐Charles Cerottini, Thierry Boon, Marie Marchand - International Journal of Cancer 1995 cited by 285

  24. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie

    Authors: S. Al-Batran, J. T. Hartmann, Ralf‐Dieter Hofheinz, Nils Homann, Volker Rethwisch, Stephan Probst, Jan Stoehlmacher, Michael Clemens, Rolf Mahlberg, Mary Ann Fritz, G. Seipelt, Mark Sievert, Claudia Pauligk, Akin Atmaca, Elke Jäger - Annals of Oncology 2008 cited by 281